visceral adiposity raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2025-10-15 and is reviewed periodically as new material appears.
Tesamorelin binds to growth hormone-releasing hormone receptors on the surface of pituitary somatotroph cells. This binding activates adenylate cyclase, raising intracellular cyclic AMP levels and triggering the release of growth hormone into circulation. The elevated growth hormone then stimulates hepatic production of insulin-like growth factor 1. Because the effect is mediated through the endogenous axis, secretion remains subject to feedback regulation. This distinguishes it from direct growth hormone administration, which bypasses pituitary control entirely.
Clinical investigation has focused on HIV-associated lipodystrophy, a condition in which antiretroviral therapy contributes to abnormal fat distribution. Excess visceral adipose tissue accumulates in the abdomen while peripheral fat may be lost. Tesamorelin was evaluated for reducing this visceral fat depot, with trials measuring changes in abdominal fat by imaging rather than by body weight alone. The rationale rests on the known lipolytic effects of growth hormone. Effects on visceral fat are documented, while long-term outcomes regarding cardiovascular risk remain less clearly established.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone, composed of 44 amino acids. It was designed to retain the biological activity of the native hormone while resisting rapid enzymatic degradation. The compound is classified as a growth hormone secretagogue and belongs to the broader family of hypothalamic releasing factors. In research and clinical settings, it is studied for its ability to stimulate pituitary growth hormone release. Its structure includes a modification at the N-terminus that contributes to an extended half-life relative to native growth hormone-releasing hormone.
Tesamorelin is a synthetic peptide of 44 amino acids that reproduces the sequence of human growth hormone-releasing hormone (GHRH) and carries a trans-3-hexenoyl group on its N-terminal tyrosine. That small fatty-acid modification blocks cleavage by dipeptidyl peptidase-4, the enzyme that rapidly degrades native GHRH in plasma. The result is a molecule with a longer circulating half-life than the natural hormone while retaining the same receptor target. It is supplied as a lyophilized powder for reconstitution and belongs to the broader class of GHRH analogs studied for effects on pituitary growth hormone secretion.
Development work on the compound, originally designated TH9507, focused on conditions in which reduced growth hormone signaling is thought to contribute to altered body composition. The United States Food and Drug Administration approved it in 2010 for the treatment of excess visceral abdominal fat in adults with human immunodeficiency virus infection and lipodystrophy. Later research examined other populations, including adults with mild cognitive impairment, where a large trial did not meet its primary endpoints. This mixed record illustrates how a single mechanism can produce clear effects in one setting and inconclusive results in another.
Several related peptides act on the same receptor, including sermorelin, a shorter GHRH fragment, and modified analogs such as CJC-1295 and modified GRF(1-29) that are common in research settings rather than approved products. Tesamorelin differs from growth hormone itself in that it acts upstream, prompting the pituitary to release the hormone through physiological signaling rather than supplying it directly. Terminology in the literature distinguishes GHRH analogs, growth hormone secretagogues, and recombinant growth hormone, although popular discussion often blurs these categories together. Precise naming matters when comparing study results.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Analog of growth hormone-releasing hormone |
| Amino acid length | 44 residues | Matches the native peptide backbone |
| Molecular weight | Approximately 5135 Da | Calculated from the peptide sequence |
| Receptor target | GHRH receptor | Expressed on pituitary somatotroph cells |
| Primary studied use | Visceral fat reduction | Investigated in HIV-associated lipodystrophy |
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic analog of growth hormone-releasing hormone, a peptide hormone produced by the hypothalamus. The molecule retains the 44-amino-acid sequence of human GHRH and carries a trans-3-hexenoyl modification at its N-terminus. This modification increases resistance to enzymatic degradation and extends the peptide's functional stability relative to native GHRH. The compound is supplied as a lyophilized powder for reconstitution and subcutaneous administration in clinical settings. Its development code was TH9507, and it belongs to the GHRH analog class. It is not a growth hormone product; instead, it acts upstream to stimulate endogenous growth hormone release.
Clinical interest in tesamorelin arose from the need to address visceral adiposity in people living with HIV. Antiretroviral therapy improved survival but was associated in some patients with central fat accumulation, altered lipid profiles, and metabolic complications. This condition, often called HIV-associated lipodystrophy, involves excess visceral adipose tissue that is difficult to manage through diet and exercise alone. Investigators evaluated tesamorelin because GHRH analogs can stimulate growth hormone secretion and influence fat distribution without direct liposuction or invasive procedures.
监管记录显示，特沙莫瑞林于 2010 年在美国首次获得批准，用于人类免疫缺陷病毒感染相关的脂肪营养不良患者。批准依据来自降低内脏脂肪的临床试验，而非体重或瘦体重的普遍改善。后续出现了不同制剂版本，但其核心适应症保持一致。关于长期心血管结局和死亡率影响，现有证据仍不充分。
在临床研究之外，特沙莫瑞林常被讨论为生长激素分泌促进剂，但这一说法需要限定。它并不等同于生长激素本身，也不属于普通减重药物。部分研究关注其减少腹部脂肪和改善脂质谱的潜力，另一些研究则关注胰岛素抵抗和 IGF-1 升高等信号。这些效应的临床意义仍在评估中，尚未形成统一结论。
May 24, 2017: Decree on responsibilities delegated to the Secretary of State for Gender Equality. October 2017: Global surge in public speaking out following the Weinstein affair: digital platforms such as Twitter host many testimonies of harassment and sexual assault under hashtags like #MeToo and #BalanceTonPorc in France. August 3, 2018: Law strengthening the fight against sexual and gender-based violence (creation of the offense of sexist insult, broader definition of online harassment, stronger penal provisions on sexual offenses against minors, and a 30-year statute of limitations from the victim's majority for sexual crimes against minors). September 5, 2018: Law on the freedom to choose one's professional future. September 10, 2018: Law on controlled immigration, effective asylum rights, and successful integration. March 23, 2019: Programming and reform law for justice (2018–2022). May 22, 2019: Law on business growth and transformation. May 27, 2019: Decree improving health and maternity coverage for self-employed workers. June 26, 2019: National action plan to eradicate female genital mutilation. July 24, 2019: Bioethics bill including access to medically assisted reproduction (ART) for female couples and single women. July 26, 2019: Law for a trustworthy school. August 6, 2019: Law transforming the civil service. December 28, 2019: Law against domestic violence. March 2020: During the COVID-19 pandemic and lockdowns, domestic violence increased significantly, highlighting the issue in society. June 24, 2020: Law combating online hate content.
== Electronic properties == Many of the properties of transition metal complexes are dictated by their electronic structures. The electronic structure can be described by a relatively ionic model that ascribes formal charges to the metals and ligands. This approach is the essence of crystal field theory (CFT). Crystal field theory, introduced by Hans Bethe in 1929, gives a quantum mechanically based attempt at understanding complexes. But crystal field theory treats all interactions in a complex as ionic and assumes that the ligands can be approximated by negative point charges. More sophisticated models embrace covalency, and this approach is described by ligand field theory (LFT) and molecular orbital theory (MO). Ligand field theory, introduced in 1935 and built from molecular orbital theory, can handle a broader range of complexes and can explain complexes in which the interactions are covalent. The chemical applications of group theory can aid in the understanding of crystal or ligand field theory, by allowing simple, symmetry based solutions to the formal equations. Chemists tend to employ the simplest model required to predict the properties of interest; for this reason, CFT has been a favorite for the discussions when possible. MO and LF theories are more complicated, but provide a more realistic perspective. The electronic configuration of the complexes gives them some important properties:
== Awards and honours == Hamley was a Royal Society-Woolfson Research Merit Award Holder 2011–2016 and won the RSC Peter Day award for Materials Chemistry in 2016 and the MacroGroup UK Medal for Contribution to UK Polymer Science in 2016.
Sources: en.wikipedia.org
The farming of fish is the most common form of aquaculture. It involves raising fish commercially in tanks, fish ponds, or ocean enclosures, usually for food. A facility that releases juvenile fish into the wild for recreational fishing or to supplement a species' natural numbers is generally referred to as a fish hatchery. Worldwide, the most important fish species used in fish farming are, in order, carp, salmon, tilapia, and catfish. In the Mediterranean, young bluefin tuna are netted at sea and towed slowly towards the shore. They are then interned in offshore pens (sometimes made from floating HDPE pipe) where they are further grown for the market. In 2009, researchers in Australia managed for the first time to coax southern bluefin tuna to breed in landlocked tanks. Southern bluefin tuna are also caught in the wild and fattened in grow-out sea cages in southern Spencer Gulf, South Australia. A similar process is used in the salmon-farming section of this industry; juveniles are taken from hatcheries and a variety of methods are used to aid them in their maturation. For example, as stated above, some of the most important fish species in the industry, salmon, can be grown using a cage system. This is done by having netted cages, preferably in open water that has a strong flow, and feeding the salmon a special food mixture that aids their growth. This process allows for year-round growth of the fish, thus a higher harvest during the correct seasons. An additional method, known sometimes as sea ranching, has also been used within the industry.
fMLF and a sampling of other, less potent, N-formyl oligopeptides were then found to stimulate a wide array of rabbit neutrophil functions such as: the transient auto-aggregation of these cells in suspension and equally transient fall in circulating neutrophils when injected into rabbit veins (these responses result from an increase in neutrophil adhesiveness to each other and/or vascular endothelium); the release (see degranulation) of intracellular granule-bound enzymes and other antimicrobial cytotoxic molecules; and the production and release of cytotoxic reactive oxygen species such as superoxide and hydrogen peroxide. All of these responses are part of the innate immune systems initial line of defense against bacterial invasions. Follow-up studies found that the genes of mitochondria and chloroplasts of eukaryotic cells, including the mitochondria of humans, release N-formyl-methionyl containing peptides with chemotactic activities that exactly mimic those of fMLF. These organelle-derived formylated peptides are true analogs of fMLF that operate through fMLF receptors to recruit circulating blood leukocytes to and thereby initiate inflammation responses at sites of cell damage and tissue destruction not caused by bacteria. Thus, fMLF can act as a find-me signal, released by dead or dying cells to attract phagocytes to those cells, so that the phagocytes phagocytose the dead or dying cells, thereby clearing up the damage. fMLF and other N-formylated oligopeptides were found to be similarly active in human neutrophils.
This is a shortened version of the thirteenth chapter of the ICD-9: Diseases of the Musculoskeletal System and Connective Tissue. It covers ICD codes 710 to 739. The full chapter can be found on pages 395 to 415 of Volume 1, which contains all (sub)categories of the ICD-9. Volume 2 is an alphabetical index of Volume 1. Both volumes can be downloaded for free from the website of the World Health Organization.
Sources: en.wikipedia.org
It is a synthetic analog of growth hormone-releasing hormone, a hypothalamic peptide. It functions as a growth hormone secretagogue acting at pituitary receptors. The classification separates it from direct growth hormone products.
The synthetic peptide incorporates modifications that slow enzymatic breakdown in circulation. Native growth hormone-releasing hormone is short-lived, whereas the analog is designed for greater stability. The core amino acid backbone is largely retained.
The main studied application is reduction of excess visceral abdominal fat in HIV-associated lipodystrophy. Research has measured fat changes through imaging. Findings concern fat distribution rather than overall body weight.
It is a synthetic peptide built from 44 amino acids arranged in the same order as human growth hormone-releasing hormone. A short fatty-acid chain, described as a trans-3-hexenoyl group, is attached to the first amino acid. The finished molecule is formulated as a sterile powder that is dissolved before use.